Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SkinBioTherapeutics ( (GB:SBTX) ) just unveiled an update.
SkinBioTherapeutics plc announced a trading update for FY25, revealing expected revenues of £4.5m-£4.8m, a significant increase from FY24, driven by acquisitions and organic sales growth. Despite slightly missing market expectations due to order timing, the company is nearing profitability with a reduced EBITDA loss. The company has a strong cash position, bolstered by a recent fundraising to support a commercial deal with Superdrug for AxisBiotix™ supplements. Post-year-end trading has been robust, and preparations for the Superdrug launch are underway, positioning the company for rapid scale and shareholder value growth.
Spark’s Take on GB:SBTX Stock
According to Spark, TipRanks’ AI Analyst, GB:SBTX is a Underperform.
SkinBioTherapeutics faces significant financial challenges with ongoing losses and cash burn, which heavily influence its stock score. While technical indicators show bearish trends, recent positive corporate events and strategic moves offer potential future benefits. However, until these translate into improved financial performance, the stock’s score remains low.
To see Spark’s full report on GB:SBTX stock, click here.
More about SkinBioTherapeutics
SkinBioTherapeutics is a life science company focused on skin health, utilizing its proprietary platform technology, SkinBiotix®, developed by the University of Manchester’s translational dermatology team. The company targets the skin healthcare market through five pillars, with a focus on cosmetic skincare and food supplements that leverage the gut-skin axis. Their products include AxisBiotix-Ps™, a supplement for inflammatory skin conditions, and they have a partnership with Croda plc. SkinBioTherapeutics is expanding through acquisitions in skincare and cosmetics, enhancing distribution and manufacturing capabilities.
Average Trading Volume: 1,245,571
Technical Sentiment Signal: Sell
Current Market Cap: £39.79M
Learn more about SBTX stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money